About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Safety Study of SGN-CD70A in Cancer Patients

NCT02216890·17 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Seagen Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large B-cell lymphoma including Grade 3b follicular lymphoma
Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies
Confirmed positive CD70 expression on tumor tissue
Eastern Cooperative Oncology Group performance status 0 or 1
Adequate baseline hematologic, pulmonary, renal, and hepatic function
Measurable disease

You may not be if

Prior treatment with anti-CD70 directed therapy unless CD70 expression is confirmed on tumor tissue obtained after the treatment
Patients \<100 days since prior allogeneic stem cell transplant
Less than 4 weeks since prior treatment; or 2 weeks if patient experienced disease progression on the prior treatment

The record

StatusCompleted

PhasePhase 1

Taking part38

StartedAug 2014

UpdatedApr 19, 2018

Conditions

Renal Cell Carcinoma Mantle-Cell Lymphoma Diffuse, Large B-Cell, Lymphoma Follicular Lymphoma, Grade 3

Where17

University of Alabama at Birmingham
Birmingham, Alabama, United States
City of Hope National Medical Center
Duarte, California, United States
Cardinal Bernardin Cancer Center / Loyola University Medical Center
Maywood, Illinois, United States

Clareo Health | Safety Study of SGN-CD70A in Cancer Patients